A man is inoculated with the Covid-19 vaccine from AstraZeneca, in Rheinbach, Germany on April 6, 2021. -
Oliver Berg / AP / SIPA
The Swedish-British group AstraZeneca is at the heart of the news this Tuesday.
The European Medicines Agency (EMA) said on Tuesday that it was still evaluating whether its vaccine against Covid-19 is potentially linked to the formation of rare blood clots, reported in several countries.
This announcement tempers the words of an EMA official, who mentioned the existence of a "link" between the AstraZeneca vaccine and the cases of thrombosis observed after its administration, in an interview with the Italian daily
Il Messaggero
published a few hours earlier this Tuesday.
An announcement this Wednesday or Thursday
The EMA security committee "has yet to come to a conclusion and the review is currently underway," the Amsterdam-based agency told AFP in a statement.
"We will communicate and organize a press point as soon as the review is finalized," added the European regulator, specifying that an announcement is currently expected Wednesday or Thursday.
Marco Cavaleri, head of vaccine strategy at the EMA, said earlier that "it is clear that there is a link with the vaccine."
Health
Coronavirus: What are the side effects of the three vaccines authorized in France?
Health
Vaccination in Nord-Pas-de-Calais: Nearly 1,500 doses of AstraZeneca do not find a taker
EU
Health
AstraZeneca
Anti-covid vaccine
Covid 19
Coronavirus